Recent publications on relapsed or refractory pediatric patients with acute myeloid leukemia.
Reference | Drugs | Response (No. of patients) |
---|---|---|
Niktoreh |
Gemtuzumab ozogamicin±other chemotherapeutic agents | 51% (36/71) |
Cooper |
CPX-351 (a liposomal preparation of cytarabine and daunorubicin) | 81% (30/37) CR/CRp/CRi |
van Eijkelenburg |
Clofarabine, liposomal daunorubicin, high-dose cytarabine | 68% (21/31) CR/CRi/PR |
Messinger |
Clofarabine, cyclophosphamide, and etoposide | 51% (9/17) CR/CRp/CRi |
Cooper |
Plerixafor, high dose cytarabine, etoposide | 23% (3/13) CR/CRp/CRi |
Horton |
Bortezomib, low-dose cytarabine, idarubicin | 57.1% (8/14) CR/CRp/CRi (cycle 1) |
Bortezomib, high-dose cytarabine, etoposide | 47.8% (11/23) CR/CRp/CRi (cycle 1) | |
Cooper |
Clofarabine, cytarabine | 45% (21/47) CR/CRp |
Shukla |
Clofarabine, topotecan, vinorelbine, thiotepa | 67% (8/12) |
Kaspers |
FLAG | 59% (117/197) |
FLAG+liposomal daunorubicin | 69% (135/197) | |
Miano |
Clofarabine, etoposide, cyclophosphamide | 44% (7/16) CR/CRi |
Inaba |
Clofarabine, cytarabine, daily sorafenib | 72% (8/11) CR/CRi |
Inaba |
Cladribine, topotecan | 35% (9/26) |
Abbreviations: CR, complete remission; CRi, complete remission with incomplete count recovery; CRp, notable CR with incomplete platelet recovery; FLAG, fludarabine, high dose cytarabine, filgrastim.